Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2017 call → NOWe need to determine if management explains the company's forward business by narrating what its counterparties are doing and scaling. The key is whether management's forward account is driven by reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies, and that this growth is early and large relative to the company. Let's analyze the transcript. Management discusses several things: new products like Nurse Residency Pathway, OB Risk program, Knowledge Q, etc. They mention specific customers: e.g., a top five account renewed early and added products, a large customer selected OB Risk program. They also discuss partnerships with Laerdal and new partners for resuscitation products. They talk about the transition from phone to online surveys, and the shift to SaaS in Provider Solutions. But the question is specifically about whether management's forward account consists of reporting on the growth, expansion, ramp, adoption, or program build-out of specific counterparties that the company already supplies, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's look for instances where management describes what a specific customer or partner is doing in terms of their own scaling, and that this drives the company's future. For example, the OB Risk program: "one of our largest customers in our entire customer base, selected our OB Risk program... for system-wide deployment in a multiyear agreement." That is a specific customer's decision, but is it described as that customer's own trajectory? Management says it's a multiyear agreement, but does it describe the customer's own expansion? Not really. It's more about the sale. Similarly, the Nurse Residency Pathway: "Christa’s Southeast Texas Hospital, Saint Elizabeth's Nurse Residency program... achieved ANCC accreditation." That is about a customer's program achieving accreditation, which helps marketing. But is that a trajectory of scaling? Not really. The resuscitation products: management discusses the transition from Laerdal to new partners. They talk about signing new strategic partners. But those partners are not yet supplying products; they are new partners. The company will sell their products in the future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.